{"timestamp":1742030337199,"guidances":[{"title":"Drug Development and Drug Interactions: Regulatory Considerations","date":"2023-01-05","type":"general","drugTerms":[],"classTerms":[],"url":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/drug-development-and-drug-interactions-regulatory-considerations","recommendations":["In vitro drug metabolism and transport studies","Clinical drug-drug interaction studies","Pharmacokinetic assessments","Model-informed approaches for clinical trials","Drug interaction labeling requirements"],"patientRecommendations":{"phase1":"Depends on study design","phase2":"Dedicated studies or subset analysis","phase3":"Population pharmacokinetic analysis"}},{"title":"Guideline for Good Clinical Practice","date":"2022-12-15","type":"general","drugTerms":[],"classTerms":[],"url":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guideline-good-clinical-practice","recommendations":["Ethical principles based on Declaration of Helsinki","Institutional Review Board/Independent Ethics Committee requirements","Informed consent procedures","Safety reporting requirements","Protocol development and amendments"],"patientRecommendations":{"phase1":"Careful monitoring of first-in-human studies","phase2":"Adequate safety monitoring","phase3":"Representative patient population","specialPopulations":"Additional safeguards for vulnerable populations"}}]}